Zenas BioPharma nears commercial pivot with Obexelimab BLA filing on deck

Zenas BioPharma (NASDAQ:ZBIO) announced that it is on track to transition into a commercial-stage company, with plans to submit its first Biologics License Application (BLA) to the U.S. Food and Drug Administration this quarter.

The filing for obexelimab, targeted at patients with Immunoglobulin G4-related disease (IgG4-RD), is based on landmark Phase 3 INDIGO data that demonstrated a 56% reduction in flare risk compared to a placebo.

The company further expects to file a Marketing Authorization Application (MAA) with the European Medicines Agency in the second half of 2026.

Beyond its lead indication, Zenas is aggressively advancing a diversified autoimmune pipeline.

The company confirmed that enrollment for its Phase 2 SunStone trial of obexelimab in systemic lupus erythematosus (SLE) is complete, with topline results expected in the fourth quarter of 2026.

Additionally, the company initiated clinical development for ZB021, its oral IL-17AA/AF inhibitor, and continues two global Phase 3 trials—PriMroSe and Monarch—evaluating orelabrutinib in patients with multiple sclerosis.

Financially, Zenas entered the second quarter with a significantly fortified balance sheet.

Year-to-date financing activities, including equity offerings and a convertible note issuance, raised $419 million in gross proceeds.

This capital influx brought total cash, cash equivalents, and investments to $718.5 million as of March 31, 2026.

Management estimates this liquidity is sufficient to fund operations into the second quarter of 2029, contingent upon achieving specific milestones and debt proceeds.

The company’s first-quarter financial performance reflected its intensive R&D cycle.

R&D expenses for the period were $60.4 million, driven by the high costs of supporting three concurrent Phase 3 programs.

General and administrative expenses stood at $16.9 million, resulting in a net loss of $81 million for the quarter.